1 / 8

Anti-inflammatory Therapeutics Asia-Pacific Market

The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Read Complete Report @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Enquire @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market/enquire-about-report

EleanaG
Download Presentation

Anti-inflammatory Therapeutics Asia-Pacific Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anti-inflammatory Therapeutics Asia-Pacific Market Research Report, 2014-2020 (Type, Mode of action, Crop Type and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com Published on : Oct 2014

  2. Report Overview The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Moreover, increasing awareness of anti-inflammatory biologics and favorable government initiatives in the Asia-Pacific region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and uncertain patent legislations, i.e., compulsory licensing in India would continue to impede the market growth. The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis was the dominant segment accounting for 41.3% of the APAC anti-inflammatory therapeutics market in 2014 and holds potential for growth during the forecast period. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis.  Read Complete Report @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market

  3. Report Overview On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for around 50% share of the Asia-Pacific anti-inflammatory therapeutics market, and is expected to grow rapidly during the forecast period. Geographically, the market is segmented into six countries namely Japan, China, India, Australia, South Korea, Indonesia and others. Among these countries, Japan holds the largest share in the Asia-Pacific anti-inflammatory therapeutics market; however, China is expected to exhibit the fastest growth during the forecast period. Major market players have adopted strategies such as collaborations, indication expansions and product launches to expand their market presence. In 2014, Novartis got marketing approval for the drug Cosentyx (secukinumab) in Japan for the treatment of psoriatic arthritis. The company has filed new patents to overcome the issues of patent expiries of their existing drugs and to gain a prominent market share. The key companies profiled in this report are Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc., Novartis AG, F. Hoffmann-La Roche AG, Eli Lily and Company, AstraZeneca PLC and Amgen. Enquire @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market/enquire-about-report

  4. Report Overview • KEY MARKET BENEFITS • The report provides a quantitative analysis of the current market and estimations during 2014–2020 that assist in identifying and capitalizing on the prevailing market opportunities • Exhaustive analysis of the Asia-Pacific anti-inflammatory therapeutics market by product type helps in understanding the types of therapeutics and their categories that are currently being used to gain prominence in future • Competitive intelligence of leading manufacturers and distributors of anti-inflammatory therapeutics helps in understanding the competitive scenario across the geographies • Comprehensive analysis of factors that drive and restrict the growth of the Asia-Pacific anti-inflammatory therapeutics market has been provided • SWOT analysis facilitates the study of internal environment of leading companies for strategic decision-making • The country-wise analyses of anti-inflammatory therapeutics market conditions have been provided in this report

  5. Report Overview • KEY MARKET SEGMENTS • The Asia-Pacific Anti-inflammatory Therapeutics Market is segmented below: • Asia-Pacific Anti-inflammatory Therapeutics Market - By Indication • Arthritis • Respiratory diseases • Multiple sclerosis • Psoriasis • Inflammatory bowel disease • Other inflammatory diseases • Asia-Pacific Anti-inflammatory Therapeutics Market - By Drug Class • Anti-Inflammatory Biologics • Non-Steroidal Anti-inflammatory drugs (NSAIDs) • Corticosteroids

  6. Report Overview • Asia-Pacific Anti-inflammatory Therapeutics Market - By Country • Japan • China • India • Australia • South Korea • Indonesia • Other APAC countries

  7. Table of Contents • CHAPTER 1    INTRODUCTION • CHAPTER 2    EXECUTIVE SUMMARY • CHAPTER 3    MARKET OVERVIEW     • CHAPTER 4    ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION • CHAPTER 5    ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS • CHAPTER 6    ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY

  8. FOR MORE DETAILS Visit us at : http://www.researchbeam.com Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com

More Related